Back to results
US 10,501,540 B2Granted
Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
AssigneeLava Therapeutics N.V.
InventorsJohannes Jelle Van Der Vliet, Renée Cornelia Gerarda De Bruin, Tanja Denise De Gruijl, Hendrik Marinus Willem Verheul
Life of this patent
Estimating the term…
Abstract
The invention is in the field of medicine and relates to immunology, and relates in particular to human Vγ9Vδ2 T cell receptor binding immunoglobulin molecules. Human Vγ9Vδ2 T cell receptor binding immunoglobulin molecules are in particular for use in medical treatment and/or useful in assays with human Vγ9Vδ2 T cells, wherein human Vγ9Vδ2 T cells may be modulated.
Claims16
A human Vγ9Vδ2 T cell receptor binding immunoglobulin molecule, comprising a CDR1 region, and a CDR2 region,
- and a CDR 3 region, wherein the CDR1, CDR2 and CDR3 regions comprise:
- the amino acid sequences set forth in SEQ ID Nos:
- 4, 5 and 6, respectively, or
- the amino acid sequences set forth in SEQ ID Nos:
- 7, 8 and 9, respectively, or
- the amino acid sequences set forth in SEQ ID Nos:
- 4, 10 and 11, respectively, or
- the amino acid sequences set forth in SEQ ID Nos:
- 12, 13 and 14, respectively, or
- the amino acid sequences set forth in SEQ ID Nos:
- 15, 16 and 17, respectively, or
- the amino acid sequences set forth in SEQ ID Nos:
- 18, 19 and 20, respectively, or
- the amino acid sequences set forth in SEQ ID Nos:
- 18, 21 and 22, respectively, or
- the amino acid sequences set forth in SEQ ID Nos:
- 23, 24 and 25, respectively, or
- the amino acid sequences set forth in SEQ ID Nos:
- 15, 28 and 29, respectively, or
- the amino acid sequences set forth in SEQ ID Nos:
- 31, 32 and 33, respectively, or
- the amino acid sequences set forth in SEQ ID Nos:
- 31, 34 and 35, respectively, or
- the amino acid sequences set forth in SEQ ID Nos:
- 44, 45 and 46, respectively.
22 more elements
Dependencies are inferred from the claim text.